Data from commercially insured children with continuous enrolment in a US insurance database from 0 to 24 months of age were analysed and stratified into 2017-2019 and 2022-2024 cohorts. Cohorts were further stratified by risk status, determined using diagnosis data and procedure codes. A complete series of vaccination was defined as the approved 4-dose regimen of any PCV vaccine (infant immunisation at 2, 4, and 6 months, and toddler immunisation at 12–15 months).
Ms Amanda C. Miles (Pfizer Inc., NY, USA) presented the results. In total, 45,254 children were included in the 2017–2019 cohort and 30,893 in the 2022–2024 cohort. Around 25% were considered at risk for pneumococcal disease, the majority (around 75%) due to immunocompromising conditions. Most children, both with and without risk factors, completed the 3-course primary PCV series. However, full series completion rates in the 2022-2024 cohort declined by 2.7% among at-risk children and by 4.7% among healthy children compared with the 2017-2019 cohort, resulting in approximately 25% of children overall having incomplete immunisation [1].
In summary, although completion rates for the complete PCV series were similar among children with and without risk conditions, coverage decreased following the COVID-19 pandemic compared to the pre-pandemic years. “Recent declines in PCV series completion rates highlight the importance of continued monitoring to ensure that young children, particularly those at increased risk, remain protected against pneumococcal disease,” the authors concluded.
- Miles AC, et al. PCV series completion by age 24 months among children with and without risk conditions in the United States. 6th ESCMID Conference on Vaccines, 10–13 September 2025, Lisbon, Portugal.
Posted on
Table of Contents: ESCMID Vaccines 2025
Featured articles
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
Pneumococcal Vaccination
A quarter of US children have incomplete pneumococcal vaccination by age 2
V116 shows promise for adults at risk of pneumococcal disease
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
The V116 pneumococcal vaccine is a new option in children at risk for pneumococcal disease
Influenza and COVID-19 Vaccination
Omicron XBB.1.5 vaccination provides effective, but rapidly waning protection in immunocompromised individuals
Intranasal COVID-19 vaccine shows promising results in preclinical mouse models
Influenza vaccine in children shows moderate, broad protection during the 2024-2025 season
Lower age is linked to reduced uptake of influenza and COVID-19 vaccination
RSV vaccination and Immunisation
Combination respiratory vaccines show promise but face key challenges
Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA
RSV immunisation: Maternal versus direct infant immunisation
European pregnant women show openness to maternal RSV vaccination
Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation
Adjuvanted RSVPreF3 can be co-administered with a COVID-19 mRNA vaccine in adults aged ≥50 years
Other Childhood and Routine Vaccinations
Pertussis vaccination: Could an intranasal vaccine help curb the rising cases of whooping cough?
Does the 2+1 vaccination schedule for Haemophilus influenzae type b increase case numbers?
Wastewater poliovirus detections in Europe may reflect seasonal infection patterns rather than consistent importation
Emerging and Future Vaccines
Where do we stand with vaccination for haemolytic streptococci?
The future looks promising for tuberculosis vaccination
Where do alternative vaccine administration routes fit in the clinical landscape?
Malaria immunisation beyond subunit vaccines: Current progress
SARI Definitions and Vaccine Effectiveness
Case definition discrepancies influence VE outcomes
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com